Manufacturer record

Levotic Pharma: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

2 batches manufactured by Levotic Pharma were declared Not of Standard Quality between February 2026 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

2 records linked to Levotic Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
2Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Feb 2026 to Feb 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

2
NSQ batches since 2026
2
Products affected
Description
Most common failure
Feb 2026
Latest alert

Flagged batches per year

2026 · 2

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Pregabalin capsules IP 300mg LPC25138Mfg 2025-12 · Exp 2027-11 The contents of Pregabalin found to be 345.40mg per Capsule (115.13%) against labeled claim of 300.0mg per capsule.Labelling SDTL, PunjabState lab Feb 2026
Gabapentin capsules IP 400mg LPC25029Mfg 2025-02 · Exp 2027-01 Description and Uniformity of WeightDescription SDTL, PunjabState lab Feb 2026

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.